Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Castelnuovo, B.
dc.contributor.author Byakwaga, H.
dc.contributor.author Menten, J.
dc.contributor.author Schaefer, P.
dc.contributor.author Kamya, M.
dc.contributor.author Colebunders, R.
dc.date.accessioned 2010-05-18T14:44:25Z
dc.date.available 2010-05-18T14:44:25Z
dc.date.issued 2008
dc.identifier.issn 0269-9370
dc.identifier.doi http://dx.doi.org/10.1097/QAD.0b013e3282f313a9
dc.identifier.other ITG-I3A
dc.identifier.other ITG-CLA
dc.identifier.other INTER
dc.identifier.other U-CTU
dc.identifier.other CLINIC
dc.identifier.other U-HIVCLI
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other UPD21
dc.identifier.other ABSTRACT
dc.identifier.uri http://hdl.handle.net/10390/6134
dc.description.abstract BACKGROUND: A pruritic papular eruption (PPE) is a common skin manifestation observed in 12-46% of persons with HIV infection living in tropical countries. OBJECTIVE: To determine whether PPE responds to HAART and whether monitoring PPE severity could be used as a clinical marker to predict virological outcome in resource-limited settings where viral load testing is not available. METHODS: The study enrolled 53 patients with PPE for at least 1 month before starting a first-line HAART regimen as part of a prospective study. CD4 cell count and viral load were measured at enrolment and every 3 months. A scoring system was developed to evaluate the PPE severity by asking two questions. Over the last month how itchy has your skin been? Over the last month how has itching interfered with your sleep? RESULTS: Median CD4 cell count was 15 cells/mul and median viral load 268 663 copies/ml. All patients initiated a regimen containing a nonnucleoside reverse transcriptase inhibitor. Mean PPE score declined from 3.9 at enrolment to 0.1 at 24 months. In 37 (86%) of the 43 patients with at least 6 months of follow-up data, the PPE disappeared and never returned. Patients with viral load > 400 copies/ml at months 9 and/or 12 had significantly higher PPE scores at months 9 to 12 than the patients with < 400 copies/ml. CONCLUSIONS: In most patients, PPE disappears during HAART and PPE severity scores were higher in patients whose first-line HAART failed to control plasma viral load. en
dc.language English en
dc.subject HIV en
dc.subject AIDS en
dc.subject Drug therapy en
dc.subject Antiretrovirals en
dc.subject Monitoring en
dc.subject CD4 lymphocyte count en
dc.subject Viral load en
dc.subject Indicators en
dc.subject Skin diseases en
dc.subject Pruritus en
dc.title Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? en
dc.type Article en
dc.citation.issue 2 en
dc.citation.jtitle AIDS en
dc.citation.volume 22 en
dc.citation.pages 269-273 en
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/18097229
dc.citation.jabbreviation AIDS en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record